Utilizing Advanced Tools to Minimize the Burden of CMV in Transplant Recipients

Activity Evaluation and Credit Application

Post Test

Please note that to receive credit you must achieve a score of at least 70%.

Physicians: Certificate of Credit will be emailed within 4 weeks of successful completion of the activity.

Pharmacists: Credit will be uploaded to CPE Monitor at the beginning of every month.

Question Title

1. Among D+/R- solid organ transplantations, which of the following is at lowest risk of CMV?

Lung

Kidney

Small bowel

Pancreas

Question Title

2. Which of the following statements is true regarding an antiviral prophylaxis approach to preventing CMV post-transplantation?

Clinical trials fail to demonstrate definitive success of prophylaxis in preventing CMV.

Currently available antiviral agents used in prophylaxis are generally safe and well tolerated.

Viremia and CMV disease often develop once prophylaxis is discontinued.

Extending prophylaxis to six months has no impact on the incidence of late-onset CMV disease compared to 3 months of prophylaxis.

Question Title

3. Which of the following tools has been used to characterize CMV-specific T cells as a means to predict patient response to CMV reactivation and infection?

NMR spectroscopy

ELISPOT

PCR

BAL

Question Title

4. When compared to placebo, the use of letermovir for prophylaxis in HSCT recipients has demonstrated:

Significant reduction in CMV infection

No difference in all-cause mortality

Significantly longer median time to engraftment

Significant increase in graft-versus-host disease

Question Title

5. Which of the following is the leading risk factor for CMV resistance?

Prolonged exposure to ganciclovir/valganciclovir

Liver transplantation

Tissue rejection within 3 months post-transplantation

Co-infection with adenovirus

Question Title

6. Ganciclovir-resistant strains of CMV commonly have mutations is which of the following genes?

UL16

UL83

UL97

UL128